Differences in tissue angiotensin II-forming pathways by species and organs in vitro

Hypertension

Volumn 32, Issue 3, 1998, Pages 514-520

  Akasu, Maki ^a   Urata, Hidenori ^a   Kinoshita, Akio ^a   Sasaguri, Manabu ^a   Ideishi, Munehito ^a   Arakawa, Kikuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme; Aorta; Chymase; Heart; Kallikrein; Lung

Indexed keywords

ANGIOTENSIN;

ADULT; AGED; ANIMAL TISSUE; AORTA; ARTICLE; DOG; FEMALE; HEART; HUMAN; HUMAN TISSUE; LUNG; MALE; MARMOSET; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SPECIES DIFFERENCE; SWINE; SYRIAN HAMSTER; VASCULARIZATION;

EID: 0031654651     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.3.514     Document Type: Article

References (45)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med. 1984;144:1947-1953.
2. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
3. Arakawa K, Ikeda M, Fukuyama J, Sakai T. A pressor formation by trypsin from renin-denatured human plasma protein. J Clin Endocrinol Metab. 1976;42:599-602.
4. Boucher R, Asselin J, Genest J. A new enzyme leading to the direct formation of angiotensin II. Circ Res. 1974;34,35(suppl I):I-203-I-212.
5. Arakawa K, Yuki M, Ikeda M. Chemical identity of tryptensin with angiotensin. Biochem J. 1980;187:647-653.
6. Arakawa K, Maruta H. Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed "kinin-tensin enzyme system." Nature. 1980;288:705-706.
7. Tonnesen MG, Klempner MS, Austen KF, Wintroub BU. Identification of a human neutrophil angiotensin II-generating protease as cathepsin G. J Clin Invest. 1982;69:25-30.
8. Wintroub BU, Schechter NB, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human and rat chymotryptic proteinases. J Invest Dermatol. 1984;83:336-339.
9. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1987;79:1-6.
10. Cornish KG, Joyner WL, Gilmore JP. Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res. 1979;44:540-544.
11. Trachte GJ, Lefer AM. Inotropic and vasoactive effects of the naturally occurring angiotensins in isolated cat cardiac muscle and coronary arteries. Res Commun Chem Pathol Pharmacol. 1979;25:419-427.
12. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984;2: 277-284.
13. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun. 1987;3:1186-1192.
14. Ideishi M, Sasaguri M, Ikeda M, Arakawa K. Substrate-dependent angiotensin II formation in the peripheral circulation. Life Sci. 1990;46: 335-341.
15. Gondo M, Maruta H, Arakawa K. Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Jpn Heart J. 1989;30:219-229.
16. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res. 1993;27:334-340.
17. Hirakata H, Fouad-Tarazi FM, Bumpus FM, Khosla M, Healy B, Husain A, Urata H, Kumagai H. Angiotensins and the failing heart: enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril. Circ Res. 1990;66:891-899.
18. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
19. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
20. Le Trong H, Neurath H, Woodbury RG. Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci USA. 1987;84:364-367.
21. Chandrasekharan UM, Sanker S, Glynias MJ, Karnik SS, Husain A. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science. 1996;271:502-505.
22. Sanker S, Chandrasekharan UM, Wilk D, Glynias MJ, Karnik SS, Husain A. Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase-1 for angiotensin II formation and degradation. J Biol Chem. 1997;272:2963-2968.
23. Ihara M, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Local angiotensin II production and human artery diseases. J Hypertens. 1996; 14(suppl 1):S136. Abstract.
24. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 1994;90:1669-1678.
25. Paananen K, Kovanen PT. Proteolysis and fusion of low density lipoprotein particles independently strengthen their binding to exocytosed mast cell granules. J Biol Chem. 1994;269:2023-2031.
26. Banovac K, De Forteza R. The effect of mast cell chymase on extracellular matrix: studies in autoimmune thyroiditis and in cultured thyroid cells. Int Arch Allergy Immunol. 1992;99:141-149.
27. Baltatu O, Nishimura H, Hoffmann S, Stoltenburg G, Haulica ID, Lippoldt A, Ganten D, Urata H. High levels of human chymase expression in pineal and pituitary glands. Brain Res. 1997;759:269-278.
28. Ikemoto F, Song GB, Tominaga M, Yamamoto K. Endogenous inhibitor of angiotensin converting enzyme in the rat heart. Biochem Biophys Res Commun. 1989;159:1093-1099.
29. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M, Marked species-difference in the vascular angiotensin II forming pathways: humans versus rodents. Jpn J Pharmacol. 1993;62:207-210.
30. Voors AA, Pinto YM, Buikema H, Grandjean JG, Urata H, Kingma JH, van Gilst WH. Preventing the effects of angiotensin II: ACE-inhibition or angiotensin II-AT1-receptor antagonism? Eur Heart J. 1995; 16(suppl):453. Abstract.
31. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997;273: H1769-H1774.
32. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91:1269-1281.
33. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens. 1994;12(suppl):S17-S22.
34. Huntley JF, Mackellar A, Newlands GF, Irvine J, Miller HRP. Mapping of the rat mast cell granule proteinases RMCPI and II by enzyme-linked immunosorbent assay and paired immunofluorescence. APMIS. 1990;98: 933-944.
35. Craig SS, Schwartz LB. Tryptase and chymase, markers of distinct types of human mast cells. Immunol Res. 1989;8:130-148.
36. Jeffery PK. Morphologic features of airway surface epithelial cells and glands. Am Rev Respir Dis. 1983;128:S14-S20.
37. Schwartz LB, Irani AA, Mroueh S, Spock A. Reserved ratio of T/TC types of human mast cells in cystic fibrosis. Clin Res. 1987;35:255A. Abstract.
38. Patella V, de Crescenzo G, Ciccarelli A, Marino I, Adt M, Marone G. Human heart mast cells: a definitive case of mast cell heterogeneity. Int Arch Allergy Immunol. 1995;106:386-393.
39. Rousseau MF, Kostam MA, Benedict CR, Donckier J, Melin J, Kinan D, Ahn S, Ketelslegers JM, Pouleur H, Galanti L. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol. 1994;73:488-493.
40. Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M, Tanaka H, Shindo M, Arakawa K. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens. 1994;12: 1177-1181.
41. Dell'Italia LJ, Meng QC, Balcells E, Straeter-Knowlen IM, Hankes GH, Dillon R, Cartee RE, Orr R, Bishop SP, Oparil S, Elton TS. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol. 1995;269:H2065-H2073.
42. Urabe Y, Ideishi M, Sasaguri M, Ikeda M, Arakawa K. Beneficial effects of a serine protease inhibitor in peripheral vascular disease. Am J Cardiol. 1993;72:218-222.
43. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
44. Ihara M, Urata H, Kinoshita A, Shirai K, Okabe M, Sasaguri M, Ideishi M, Suzumiya J, Kikuchi M, Arakawa K. Increased angiotensin II-forming activity in the infarcted and non-infarcted myocardium in patients with acute myocardial infarction. J Hypertens. 1998;16(suppl 2):S118. Abstract.
45. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet. 1997;349:747-752.